



## Lipomics Technologies Hires Chief Medical Officer

*CMO to direct Lipomics' entry into the field of clinical diagnostics with lipid-based metabolic tests.*

WEST SACRAMENTO, Calif., Sept. 6, 2006 – Lipomics Technologies, Inc., a company specializing in the comprehensive and quantitative profiling of lipid metabolites, announced today that Dr. Meeta Patnaik, MD has joined the company in the newly created position of Chief Medical Officer.

Dr. Patnaik comes to Lipomics with twenty years of experience in medicine, immunology, virology, molecular biology and has developed and marketed over 200 clinical assays, including the first commercially available test for Hanta virus. Dr. Patnaik will be responsible for developing Lipomics' rich pipeline of diagnostic products leveraging their proprietary database of lipid metabolites to identify disease states.

Previously, Dr. Patnaik was senior VP and chief science and technology officer at Pathway Diagnostics. There she was responsible for all aspects of the scientific and commercialization of new diagnostic assays and was part of the licensing and IP team. She also enabled several key alliances with major diagnostic and drug development partners.

“Meeta’s broad and deep experience will enable Lipomics to develop and commercialize specific lipid-based diagnostic assays helping to grow our clinical diagnostics program,” said Steve Watkins, Ph.D., Lipomics’ president and chief scientific officer. “We are very pleased and most fortunate to have her join us at Lipomics.”

“Metabolic disease is pervasive and lipid-based diagnostics will fill severely underserved needs in both drug development and patient treatment,” said Dr. Meeta Patnaik, Lipomics’ chief medical officer. “Lipomics is ideally positioned with unique expertise to drive improved and personalized management of a large range of major disease states.”

Dr. Patnaik received her MD in 1987 and was a research fellow in immunology at the National Institute of Immunology in New Delhi, India. She has also held long-term academic positions at the Department of Clinical Laboratory Sciences, California State University, Dominguez Hills and the Department of Biotechnology, Microbiology and Immunology, University of California, Los Angeles. Patnaik is also the author of over 69 published scientific papers and journal articles and has presented papers at a number of professional and academic institutes worldwide.

## About Lipomics Technologies, Inc.

Lipomics Technologies provides industry-leading metabolic profiling for drug discovery and development, clinical diagnostics and personalized medicine. The Company's proprietary analytical technologies generate a comprehensive, accurate and quantitative profile of lipid metabolites. A broad range of bioinformatics and analytical tools map these profiles to activities of underlying biochemical pathways. Through these tools, Lipomics delivers deep and rich knowledge about biological and metabolic changes induced by disease, drug action, nutritional or lifestyle influences. In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technologies to discover new biomarkers, accelerate drug discovery, improve clinical trial stratification, reduce late-stage drug attrition, develop early tests for monitoring drug response and enable individualized health management. More information about Lipomics can be found at [www.lipomics.com](http://www.lipomics.com) .

###

### EDITORIAL CONTACTS:

Sarina Chohan  
(916) 371-7974  
[schohan@lipomics.com](mailto:schohan@lipomics.com)

### Agency Contact

Doug Forsyth, Alchymia Communications® LLC  
(541) 482-8744  
[df@alchymiacomm.com](mailto:df@alchymiacomm.com)